Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2019 March;58(1) > Minerva Pneumologica 2019 March;58(1):27-35

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Pneumologica 2019 March;58(1):27-35

DOI: 10.23736/S0026-4954.19.01840-6

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Early noninvasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia

Antonello NICOLINI 1 , Lara PISANI 2, Catia CILLÓNIZ 3, 4, 5, Gianluca FERRAIOLI 6

1 Unit of Respiratory Diseases, Hospital of Sestri Levante, Sestri Levante, Genoa, Italy; 2 Unit of Respiratory and Critical Care, Department of Cardiac-Thoracic and Vascular Diseases, University Hospital St. Orsola-Malpighi, Bologna, Italy; 3 Department of Pneumology, Clinical Institute of Thorax, Hospital Clinic of Barcelona, Barcelona, Spain; 4 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; 5 Ciber de Enfermedades Respiratorias (Ciberes), Barcelona, Spain; 6 Emergency Department, Tigullio Hospital, Lavagna, Genoa, Italy



INTRODUCTION: Acute respiratory failure (ARF) frequently complicates severe community-acquired pneumonia (CAP) that together with sepsis increases patient mortality. The background of the noninvasive ventilation (NIV) use is to overcome an episode of ARF avoiding invasive mechanical ventilation (IMV) and its associated morbidity.
EVIDENCE ACQUISITION: We performed a systematic review of the available English literature published up to December 2018 inclusive and focused on ARF in adult CAP population. Database searches identified 177 articles; of these, only 16 were retained for data extraction.
EVIDENCE SYNTHESIS: After analyzing all data, we observed that uncertainties in the current literature do not allow firm and definitive recommendations concerning the early use of NIV in hypoxemic CAP patients. IMV still remains a standard of care for many cases of severe CAP.
CONCLUSIONS: Nonetheless, NIV is part of our armamentarium and some optimally selected patients clearly benefit from its use. However, in this setting NIV can be considered a valid and useful strategy in some well-selected patients.


KEY WORDS: Respiratory insufficiency - Pneumonia - Noninvasive ventilation

top of page